Immune cancer prevention · 2026
DC + NKT + WT1 + MUC1,
three effects in one.
A broad-spectrum immune cancer-prevention protocol pairing cellular therapy with tumor-antigen vaccine technology — NKT-driven immune activation, DC reinforcement and WT1/MUC1 antigen-specific priming. Delivered as registered clinical research at China’s Class A hospitals, with the evidence graded honestly.
3-in-1
Immune activation
Activation · supplementation · antigen-specific priming
Protocol design
VA24JA18
Invariant iNKT TCR
Binds CD1d on antigen-presenting cells
Immunology
2
Tumor antigens targeted
WT1 (WT1-PLUS vaccine) + MUC1
Protocol design
21–36 days
Course length
By risk group (healthy vs high-risk)
Protocol schedule
Class A
All partner facilities
NMPA-licensed GMP-grade cell labs
NHC / NMPA
12 mo
Follow-up included
Telehealth review with operating physician
PandaTouring Care
The concept
Immunotherapy plus a
tumor-antigen vaccine.
NKT cells are a special class of lymphocyte that can recognise and attack tumor and infected cells while also regulating the activity of other immune cells. In this protocol NKT cells are infused while the immune system is at its most responsive, then a WT1-PLUS anti-tumor vaccine is given — so the two act synergistically.
Research indicates NKT cells can raise the immunogenicity and anti-tumor effect of the WT1-PLUS vaccine by releasing IFN-γ, and can strengthen how other immune cells respond to the WT1 and MUC1 antigens — further improving the response. The result is designed as “three effects in one”: immune activation, immune reinforcement, and antigen-specific stimulation.
We present this the way we present every cellular therapy on this site: honestly. Tumor-antigen vaccines and NKT immunotherapy are promising but remain investigational for broad cancer prevention. PandaTouring Care delivers it only through NMPA-licensed Class A hospitals under registered clinical research, and only where a physician judges it appropriate.
Mechanism of action
How the protocol works.
NKT cells — the master switch
Invariant natural killer T (iNKT) cells express the TCR VA24JA18, which engages CD1d on antigen-presenting cells. Once activated they can simultaneously mobilise CD8+ T cells and NK cells — clearing both MHC-positive and MHC-negative tumor cells that either arm alone would miss.
DC maturation & antigen uptake
Activated NKT cells interact with immature dendritic cells via CD1d and CD40L–CD40, driving DC maturation. Mature DCs rapidly take up the WT1 and MUC1 tumor-antigen peptides and present them to CD4+ memory cells — building durable, long-term anti-tumor immunity.
IL-12 / IFN-γ feedback loop
On activation, iNKT cells release IFN-γ and engage DCs through CD40L–CD40. DCs respond with IL-12, which further stimulates the iNKT cells — a positive-feedback circuit that amplifies the whole response rather than a single-shot stimulus.
WT1-PLUS vaccine synergy
Priming with NKT cells before the WT1-PLUS antigen vaccine is designed to raise vaccine immunogenicity: NKT-driven IFN-γ boosts DC antigen presentation and T-cell activation, so the subsequent vaccine mounts a stronger, antigen-specific anti-tumor response.
Working principle
Four ways NKT cells
amplify the vaccine.
Activate dendritic cells
By secreting IFN-γ and related cytokines, NKT cells stimulate DC maturation and activation — strengthening how DCs present vaccine antigen and prime T cells.
Activate T cells
NKT cells activate T cells directly or via DCs and promote their proliferation and differentiation in vivo — enhancing the vaccine-induced T-cell response.
Activate NK cells
Through IFN-γ and other cytokines, NKT cells activate natural killer cells, boosting their cytotoxicity against tumor cells and further raising the anti-cancer effect.
Enhance antibody production
Via IFN-γ, IL-4 and IL-21, NKT cells drive B-cell activation and differentiation, strengthening the antibody response the vaccine induces.
Before the WT1-PLUS vaccine, NKT cells prime the immune response through several routes at once — maturing dendritic cells, activating T and NK cells and supporting antibody production — which is intended to raise the vaccine’s effectiveness and its protective effect against disease.
Who it’s for
Six candidate groups.
Sub-health individuals
People with sub-optimal health seeking to restore normal physiological function and immune balance.
Healthy people & family cancer history
Those wanting to raise immune competence and reduce disease and cancer risk — particularly with a hereditary or high-susceptibility genetic background.
Cancer patients — as an adjunct
Delivered alongside conventional oncology to support resistance, complement standard treatment and help mitigate side effects. Never a stand-alone replacement for cancer treatment.
Cancer survivors
Individuals in stable remission after treatment, focused on lowering the risk of recurrence and metastasis under physician supervision.
Anti-ageing goals
People seeking endocrine regulation and general immune support as part of a longevity plan.
Low immunity
Those with a weakened or declining immune system looking to improve and protect immune function.
Treatment schedule
Dosing by risk group.
| Candidate group | Cycle | Day | Treatment |
|---|---|---|---|
| Healthy / sub-health Standard For healthy and sub-health individuals. | 21 days | Day 1 | NKT immune-cell therapy (5 billion units) + WT1-PLUS anti-tumor vaccine |
| Day 2 | NKT immune-cell therapy (5 billion units) | ||
| Day 21 | WT1-PLUS anti-tumor vaccine | ||
| Hereditary / high-susceptibility genes High-risk High-risk group with tumor-related genetic / susceptibility markers. | 36 days | Day 1 | NKT immune-cell therapy (10 billion units) + WT1-PLUS vaccine |
| Day 15 | DC cells (>10 million units) + WT1-PLUS vaccine | ||
| Day 36 | WT1-PLUS anti-tumor vaccine | ||
| Abnormal tumor markers High-risk Abnormal tumor markers or early tumor-cell mutation detected. | 36 days | Day 1 | NKT immune-cell therapy (10 billion units) + WT1-PLUS vaccine |
| Day 15 | DC cells (>10 million units) + WT1-PLUS vaccine | ||
| Day 36 | DC cells (>10 million units) + WT1-PLUS vaccine | ||
| Malignancy / recurrence-prevention Physician-assessed Patients mid-treatment, or stable after prior cancer treatment. | Individualised | Combined with standard care | Regimen set by a qualified physician based on changes in the patient's tumor-related markers and clinical picture. |
Schedules and cell dosing are indicative and set individually by the treating physician after case review. For active malignancy the regimen is combined with conventional treatment and adjusted to the patient’s tumor-marker changes — never delivered as a stand-alone alternative to standard cancer care.
Cell source
Autologous blood vs
cord-blood NKT.
Autologous peripheral-blood NKT
- Easy to obtain — mature immune cells drawn from the adult's own circulating blood.
- Fully developed — matured through natural development in peripheral organs (spleen, lymph nodes), with high activity and function.
- Broad recognition — non-selective binding to CD1d-presented antigens lets them interact with, and kill, many cell types.
- Immune memory — remembers responses to specific antigens, reacting faster and more effectively on re-exposure.
Cord-blood (neonatal) NKT
- Higher cell numbers — cord blood is rich in NKT cells, more abundant than adult blood, so large quantities are easier to obtain.
- Immunologically naïve — produced in the fetal stage, more sensitive to stimulation and easier to activate and modulate.
- Highly versatile — broad regulatory reach over other immune cells (T, B, DC), with wide potential in autoimmune and cancer settings.
- Less immune memory — being naïve, lower self-antigen memory helps avoid autologous immune reactions, an advantage for transplantation-style protocols.
FAQ
The protocol, answered.
- What is the DC+NKT+WT1+MUC1 broad-spectrum immune cancer-prevention protocol?
- It is a combination immunotherapy that pairs cellular therapy with tumor-antigen vaccine technology — three effects in one: immune activation (NKT cells), immune reinforcement (DC cells), and antigen-specific priming (WT1 and MUC1 tumor antigens via the WT1-PLUS vaccine). NKT cells are infused while the immune system is most responsive, then a WT1-PLUS anti-tumor vaccine is administered so the two work synergistically. It is delivered as registered clinical research at Class A hospitals, not as a licensed drug.
- How do NKT cells actually help?
- Invariant NKT (iNKT) cells are a special lymphocyte that can recognise and attack tumor and infected cells while also regulating other immune cells. Through their VA24JA18 TCR they engage CD1d on antigen-presenting cells; on activation they release IFN-γ, mature dendritic cells, and switch on both CD8+ T cells and NK cells. Priming with NKT cells before a WT1-PLUS vaccine is designed to raise the vaccine's immunogenicity and anti-tumor effect.
- What is the difference between NKT and NK cells?
- They are not the same. NK (natural killer) cells are innate cytotoxic cells that kill tumor and virus-infected cells directly. NKT cells are a bridge between innate and adaptive immunity — they express a T-cell receptor (VA24JA18), respond to lipid antigens on CD1d, and orchestrate DCs, T cells, NK cells and B cells. This protocol uses NKT cells as the coordinating 'master switch'; see our separate NK-cell therapy page for NK cells specifically.
- Autologous peripheral-blood NKT or cord-blood NKT — which is used?
- Both have roles. Autologous peripheral-blood NKT are mature, easy to collect from the patient's own blood, broadly reactive and carry immune memory. Cord-blood NKT are more numerous, immunologically naïve, easier to activate, highly versatile in regulating other immune cells, and carry less self-antigen memory — an advantage in transplant-style settings. The physician selects the source based on the indication and the patient's own biology.
- Who is this protocol for?
- Six groups: sub-health individuals; healthy people and those with a family cancer history; cancer patients as an adjunct to standard care; cancer survivors focused on recurrence prevention; people with anti-ageing goals; and those with low immunity. Course length and cell dosing differ by risk group — 21 days for standard/healthy candidates, 36 days for high-risk (hereditary markers or abnormal tumor markers), and an individualised regimen for active malignancy set by a physician.
- Is this a cure or a guaranteed way to prevent cancer?
- No — and we will not claim otherwise. Cellular immunotherapy and tumor-antigen vaccines like WT1/MUC1 are promising but remain investigational for broad cancer prevention; the high-quality evidence supporting them is still developing. For cancer patients this is strictly an adjunct to conventional treatment, never a replacement. We grade the evidence honestly, deliver only through NMPA-licensed Class A hospitals under registered clinical research, and decline candidates for whom it is not appropriate.
- How do international patients access it and what does it cost?
- Through the international department of an NMPA-licensed Class A hospital with English-speaking coordination. PandaTouring Care manages case review, eligibility assessment, M-visa, on-site treatment and 12-month follow-up. Pricing is protocol- and dosing-dependent (course length, NKT unit count, DC cells, number of WT1-PLUS doses) — request an itemized written quote after case review.
Explore the cluster
Cell Therapy in China
The parent hub — stem cells, immune cells, exosomes and banking under one NMPA-regulated framework.
Read the cell-therapy hubNK-Cell Therapy
Natural killer cells — the innate first responders NKT cells help mobilise.
Read on NK cellsImmune Cell Therapy
NK, CIK, DC-CIK and CAPRI cells — how they work and the honest regulatory reality.
Read on immune cellsWT1 Cancer Vaccine
The WT1 tumor-antigen vaccine at the centre of this protocol, explained in depth.
Read on WT1Cancer Prevention in China
Screening, early detection and prevention pathways for high-risk and healthy candidates.
Read on preventionCAR-T Therapy
NMPA-approved CAR-T cellular immunotherapy for specific blood cancers.
Read on CAR-THonest candidacy
assessment, free.
Submit your records and tumor-marker history and a senior physician will tell you straight whether the DC+NKT+WT1+MUC1 protocol is appropriate for you, which cell source fits, and what realistic outcomes look like.